Keunbong (KB) Do leverages his industry experience and Ph.D. in biophysical chemistry to assist clients with patent prosecution strategy and U.S. Food & Drug Administration (FDA) regulatory matters, representing pharmaceutical, device, biotech, and food companies.

KB is experienced in strategically drafting patent applications, prosecuting and managing patent portfolios in the U.S. and internationally, and conducting intellectual property due diligence, including patentability and freedom-to-operate assessments.

He also counsels clients on FDA regulatory matters related to drugs, devices, and biological products. His experience includes analytical and clinical study design, current good manufacturing practice (CGMP) requirement analysis, premarket submissions, and FDA interactions.

KB received his J.D. from Harvard Law School. At Harvard, he received an Irving Oberman Memorial Prize for his paper on standard essential patents. Before law school, he worked at Samsung SDI as a leader of the Chemical-Mechanical Planarization (CMP) slurry development team and as a senior research engineer in the semiconductor materials development group.

He earned his Ph.D. in biophysical chemistry from Stanford University, where he was a John Stauffer Stanford Graduate Fellow and a Korea Foundation for Advanced Studies Fellow. His research focused on characterizing and engineering fluorescent proteins using molecular biology, biochemistry, and physical chemistry techniques.

KB received his B.S. summa cum laude in chemistry from Seoul National University. He also served as a sergeant in the Republic of Korea Army.

He is admitted to practice in California, New York, and Massachusetts and is a native Korean speaker.